Actuate Therapeutics, Inc. (ACTU)
| Market Cap | 167.58M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -28.45M |
| Shares Out | 19.53M |
| EPS (ttm) | -7.37 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 39,756 |
| Open | 8.80 |
| Previous Close | 8.86 |
| Day's Range | 8.58 - 8.94 |
| 52-Week Range | 5.51 - 10.16 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 13, 2024 |
About ACTU
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was i... [Read more]
News
Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development
CHICAGO and FORT WORTH, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developi...
Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma
CHICAGO and FORT WORTH, Texas, Sept. 09, 2024 (GLOBE NEWSWIRE) -- – Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on develo...
Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference
CHICAGO and FORT WORTH, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on develop...
U.S. IPO Weekly Recap: WeRide Reschedules While 6 New Filers Join The Pipeline
This week was another slow week for pricings, with two companies making their public debut, along with three SPACs. On the filing side, offshore-focused drilling equipment and aftermarket service prov...
Actuate Therapeutics Announces Closing of Initial Public Offering
CHICAGO and FORT WORTH, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Nasdaq: ACTU) (the “Company”), a clinical stage biopharmaceutical company focused on developing therapies f...
Actuate Therapeutics Announces Pricing of Initial Public Offering
CHICAGO and FORT WORTH, Texas, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Nasdaq: ACTU) (the “Company”), a clinical stage biopharmaceutical company focused on developing therapies f...
U.S. IPO Weekly Recap: August Kicks Off With One Small Pricing
U.S. IPO Weekly Recap: August Kicks Off With One Small Pricing
U.S. IPO Weekly Recap: Insurance And Healthcare Lead A 4 IPO Week
A handful of IPOs priced this past week, led by three sizable names. One large issuer joined both the pipeline and the calendar - Chile-based LATAM Airlines Group. Six IPOs are scheduled to list in th...
Actuate Therapeutics Seeks IPO For Promising Pancreatic Cancer Drugs
Actuate Therapeutics, Inc. has filed for a $50 million IPO to raise funds for its treatments for pancreatic cancer and other cancer conditions. The global market for pancreatic cancer treatment is for...
Actuate Therapeutics Files Registration Statement for Initial Public Offering
Actuate Therapeutics, Inc. announced today that it has filed a registration...
Cancer biotech Actuate Therapeutics files for a $50 million IPO
Actuate Therapeutics, a Phase 2 biotech developing in-licensed inhibitor therapies for difficult to treat cancers, filed on Friday with the SEC to raise up to $50 million in an initial public offering...
Actuate Therapeutics IPO Registration Document (S-1)
Actuate Therapeutics has filed to go public with an IPO on the NASDAQ.